...increased risk of developing cardiac surgery associated AKI showed that the highest dose of IV THR-184...
...of THR-184 administered prior to and after surgery. Thrasos Therapeutics Inc. , Montreal, Quebec Product: THR-184...

...enrollment of 452 patients in the double-blind, placebo-controlled, North American Phase II trial evaluating IV THR-184...
...6, 2014). Data are expected by January 2016. Thrasos Therapeutics Inc. , Montreal, Quebec Product: THR-184...

...Co also participated. In 3Q15 Thrasos plans to complete an ongoing Phase II study of THR-184...

...continuation of a double-blind, placebo-controlled, North American Phase II trial evaluating 3 doses of IV THR-184...
...the trial to about 450 patients undergoing cardiac surgery. The trial has enrolled 200 patients. THR-184...
...the U.S. to prevent cardiac surgery associated AKI. Thrasos Therapeutics Inc. , Montreal, Quebec Product: THR-184...

...Co in the round. Thrasos is preparing to begin Phase II testing next half of THR-184...

...proteins that would bind to ACVRI and BMPRIA but not BMPRIB. Andrews said lead compound THR-184...
...present the preclinical data at the American Society of Nephrology meeting in Philadelphia in November. THR-184...
...patients or patients with diabetes or chronic kidney disease (CKD). Thrasos also is considering developing THR-184...

...IV THR-184 in up to 72 healthy volunteers. Thrasos Innovation Inc. , Montreal, Quebec Product: THR-184...